Doctors often use a blood test called AFP to check for liver cancer, but it sometimes misses cases. A large review looked at a new marker named PTX3 to see if it helps. They studied 1,179 adults with liver problems who might have cancer. The results show PTX3 is good at finding the disease when used by itself.
When doctors used both PTX3 and AFP together, the test became much better. This combined approach found ninety-two percent of the cancer cases. It also kept the rate of false alarms low, meaning fewer healthy people get worried unnecessarily. The new marker performed very similarly to the older test on its own.
This study suggests that adding PTX3 to current checks could help doctors catch liver cancer sooner. Finding the disease early gives patients more options for treatment. More research is needed to confirm these results in different hospitals and patient groups.